公开(公告)号：US20230374549A1

公开(公告)日：2023-11-23

申请号：US18028975

申请日：2021-09-29

Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.

Inventor： Lauren Marie BEECH ,  Jesse Jerome SMITH ,  Rahul KARNIK ,  Kendrick Alan GOSS ,  Adam Walter SCHEIDEGGER ,  Jodi Michelle KENNEDY ,  Jeremiah Dale FARELLI ,  Houda BELAGHZAL ,  Laura Anh NGUYEN ,  Charles W. O'DONNELL

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/11 ,  C12N9/10 ,  C12N9/80 ,  A61P37/06 ,  A61K35/12 ,  A61K38/46 ,  A61K31/7088 ,  C07K14/47

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/11 ,  C12N9/1007 ,  C12Y201/01043 ,  C12N9/80 ,  C12Y305/01098 ,  A61P37/06 ,  A61K35/12 ,  A61K38/465 ,  A61K31/7088 ,  C07K14/4703 ,  C12Y201/01037 ,  C12Y201/01072 ,  C12N2310/20 ,  A61K2035/122 ,  C07K2319/00

Abstract: The present disclosure relates to site-specific disrupting agents for modulating, e.g., decreasing, expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprises pro-inflammatory genes, e.g., CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the method comprises using a first site-specific disrupting agent that targets a first anchor sequence and a second site-specific disrupting agents that disrupts a second anchor sequence.

公开(公告)号：US20180256749A1

公开(公告)日：2018-09-13

申请号：US15760765

申请日：2016-09-16

Applicant: University of Massachusetts

Inventor： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC: A61K48/00 ,  A61K31/496 ,  A61K31/713 ,  A61K31/549 ,  A61K31/706 ,  A61K31/5377 ,  A61K39/395 ,  A61K38/45 ,  A61K38/53 ,  A61K31/711 ,  A61K31/7105 ,  A61K35/30 ,  C12N15/113 ,  C12Q1/6883 ,  A61P25/14 ,  A61P15/02

CPC classification number: A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US09963705B2

公开(公告)日：2018-05-08

申请号：US15034092

申请日：2014-11-10

Applicant: New England Biolabs, Inc.

Inventor： Sriharsa Pradhan ,  Pierre O. Esteve ,  Guoqiang Zhang

IPC: C12N15/113 ,  A61K31/7105

CPC classification number: C12N15/1137 ,  A61K31/7105 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/151 ,  C12N2320/30 ,  C12Y201/01037

Abstract: RNA molecules inhibiting a DNMT and methods and compositions incorporating or generating the RNA molecules are described.

公开(公告)号：US20170342448A1

公开(公告)日：2017-11-30

申请号：US15314227

申请日：2015-05-28

Applicant: Reliance Industries Limited

Inventor： Gautam Das ,  Santanu Dasgupta ,  Venkatesh Prasad ,  Vinodhkumar Vijayakumar ,  Pranali Deore ,  Kannadasan Kaliyamoorthy ,  Sujata Kumari

IPC: C12P7/64 ,  C12N15/10 ,  C12N1/12 ,  C12P7/00 ,  C11C3/00

CPC classification number: C12P7/6463 ,  C11C3/00 ,  C12N1/12 ,  C12N9/1007 ,  C12N9/1029 ,  C12N15/102 ,  C12N15/65 ,  C12N15/74 ,  C12P7/00 ,  C12R1/01 ,  C12Y201/01037 ,  C12Y203/01031

Abstract: The present disclosure relates to a method for increasing lipid content in microorganisms. The method comprises decreasing the expression of molecules involved in the protein synthesis to decrease protein synthesis and thereby increase lipid synthesis in the microorganisms. The present disclosure also provides a modified microorganism having increased lipid content.

公开(公告)号：US20160272977A1

公开(公告)日：2016-09-22

申请号：US15034092

申请日：2014-11-10

Applicant: NEW ENGLAND BIOLABS INC.

Inventor： Sriharsa Pradhan ,  Pierre O. Esteve ,  Guoqiang Zhang

IPC: C12N15/113 ,  A61K31/7105

CPC classification number: C12N15/1137 ,  A61K31/7105 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/151 ,  C12N2320/30 ,  C12Y201/01037

Abstract: RNA molecules inhibiting a DNMT and methods and compositions incorporating or generating the RNA molecules are described.

Abstract translation: 描述了抑制DNMT的RNA分子以及掺入或产生RNA分子的方法和组合物。

公开(公告)号：US20140171492A1

公开(公告)日：2014-06-19

申请号：US14111971

申请日：2012-04-13

Applicant: Annalisa Di Ruscio ,  Alexander K. Ebralidze ,  Daniel G. Tenen ,  Giuseppe Leone

Inventor： Annalisa Di Ruscio ,  Alexander K. Ebralidze ,  Daniel G. Tenen ,  Giuseppe Leone

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N15/1137 ,  C12N15/635 ,  C12N2310/113 ,  C12N2310/13 ,  C12N2310/333 ,  C12N2310/334 ,  C12N2320/31 ,  C12Y201/01037 ,  C12N2310/14 ,  C12N2310/531

Abstract: The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder.

Abstract translation: 本发明涉及作为单链寡核苷酸的嵌合RNA寡核苷酸。 这些化合物能够靶向特定基因并降低DNA甲基转移酶活性。 因此，这些化合物特别可用于治疗与异常DNA甲基转移酶活性相关的疾病，例如癌症或遗传性疾病。

公开(公告)号：US11819554B2

公开(公告)日：2023-11-21

申请号：US15760765

申请日：2016-09-16

Applicant: University of Massachusetts

Inventor： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC: A61K31/711 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/395 ,  A61K48/00 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/706 ,  A61K31/713 ,  C12Q1/6883 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/404 ,  A61K31/546 ,  A61K31/167 ,  A61K31/497 ,  A61K31/506 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/522 ,  A61K31/496 ,  A61P25/14 ,  A61P15/02 ,  A61K31/7105

CPC classification number: A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/711 ,  A61K31/713 ,  A61K31/7105 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US11814623B2

公开(公告)日：2023-11-14

申请号：US16231129

申请日：2018-12-21

Applicant: University of Massachusetts

Inventor： Louis M. Messina

IPC: C12N15/113 ,  A61K35/28 ,  A61K31/19 ,  A61P17/02 ,  A61K31/7052

CPC classification number: C12N15/1137 ,  A61K31/19 ,  A61K31/7052 ,  A61K35/28 ,  A61P17/02 ,  C12Y106/03001 ,  C12Y201/01037 ,  C12N2310/11 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/31

Abstract: Methods of treating wounds in a subject using one or both of a DNA methyltransferase 1 (DNMT1) inhibitor or a nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) inhibitor, and compositions for use in these methods.

公开(公告)号：US20230183793A1

公开(公告)日：2023-06-15

申请号：US17999260

申请日：2021-05-19

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Rahul Kohli ,  Tong Wang ,  Emily Schutsky

IPC: C12Q1/6858 ,  C12N9/10

CPC classification number: C12Q1/6858 ,  C12Y201/01037 ,  C12N9/1007 ,  C12Q1/6806

Abstract: Compositions and methods for carboxymethylation of cytosine containing DNA and applications thereof for direct sequencing of 5mC are disclosed.

公开(公告)号：US20190233805A1

公开(公告)日：2019-08-01

申请号：US16151895

申请日：2018-10-04

Applicant: The Regents of the University of California

Inventor： David J Segal ,  Henriette O'Geen ,  Joel P. Mackay ,  Peggy J. Farnham

IPC: C12N9/22 ,  C12N9/10 ,  C07K14/47

CPC classification number: C12N9/22 ,  C07K14/4702 ,  C07K2319/09 ,  C07K2319/43 ,  C07K2319/81 ,  C12N9/1007 ,  C12Y201/01037 ,  C12Y201/01043

Abstract: Provided herein are fusion proteins comprising a catalytically inactive Cas9 domain and an effector domain. The fusion proteins of the present invention can be used to, for example, produce epigenetic modifications at target chromatin sites. Nucleic acids and expression vectors encoding the fusion proteins, as well as cells comprising the fusion proteins, are also provided herein.